| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18699 R79534 |
Mazzone (Carbamazepine) (Controls exposed to LTG) (Mixed indications), 2025 | Postpartum hemorrhage | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.95 [0.77;1.16] C excluded (control group) |
197/600 500/1,469 | 697 | 600 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18700 R79542 |
Mazzone (Carbamazepine) (Controls unexposed, NOS) (Mixed indications), 2025 | Postpartum hemorrhage | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 1.00 [0.79;1.27] | 197/600 203,226/624,794 | 203,423 | 600 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9751 R34819 |
Borthen (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2010 | Haemorrhage ≥ 500 ml | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.79 [0.52;1.19] C excluded (control group) |
66/388 48/233 | 114 | 388 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9753 R34827 |
Borthen (Carbamazepine) (Controls unexposed, disease free), 2010 | Haemorrhage ≥ 500 ml | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
1.30 [1.00;1.70] excluded (control group) |
66/388 49,252/362,302 | 49,318 | 388 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9755 R34835 |
Borthen (Carbamazepine) (Controls unexposed, sick), 2010 | Haemorrhage ≥ 500 ml | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No | 1.18 [0.88;1.58] C | 66/388 276/1,863 | 342 | 388 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 2 studies | 1.07 [0.89;1.28] | 203,765 | 988 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Carbamazepine) (Controls unexposed, NOS) (Mixed indications; 2: Carbamazepine) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9751, 9753, 18699